Clinical trials: Absorption; Disorder
Short Bowel Syndrome
The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
The purpose of this trial is to investigate the long-term effect of glepaglutide on the intestinal absorption, nutritional status of participants with Short Bowel Syndrome (SBS).
- Trial name
- EASE SBS 4 (NCT04991311)
- Testing
- Glepaglutide
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Zealand Pharma
RDS of Prematurity, Preterm Birth
Study to Assess Safety and Performance of Neola®, a Novel Lung Monitoring Device for Neonates
Clinical pilot study to assess safety and performance of Neola®, a novel lung monitoring device for neonates
- Conditions
- RDS of Prematurity, Preterm Birth, Lung Diseases
- Trial name
- NCT06917326
- Testing
- Monitoring
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- Neola Medical AB
Psoriasis
Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males
The purpose of this study is to evaluate sites of gut absorption of BMS-986165 in males
- Trial name
- NCT03873415
- Testing
- BMS-986165
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Chronic Small Plaque Psoriasis
Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis
The primary objective of the study is to evaluate the safety and tolerability of 50, 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with plaque psoriasis
- Trial name
- NCT00396422
- Testing
- RWJ-445380
- Volunteers
- 60 people
- Sponsor
- Alza Corporation, DE, USA
Dyslipidemia
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
The main aim of this study is to assess the effects of AZD0780 when added on top of ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.
- Trial name
- NCT06742853
- Testing
- AZD0780, Ezetimibe, Rosuvastatin
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Metabolic Disorder; Carbohydrate, Absorption, Intestine
Determination of the Postprandial Responses to Two Cereal Foods Differing by Their SDS Content Consumed Alone.
This study aimed at determining the 4-hours postprandial blood glucose and insulin responses to the ingestion of cereal product differing by their SDS content.
- Trial name
- NCT02538653
- Testing
- Sandwich biscuit high in SDS, Co-extruded cereal low in SDS
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mondelēz International, Inc.
Acne
Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream
The Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison with Tazorac Cream.
- Trial name
- NCT02849873
- Testing
- IDP-123 Lotion, Tazorac Cream
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Bausch Health Americas, Inc.
Healthy Volunteer, Muscular Dystrophies
Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
This is a Phase 1 2-part, single-center, open-label study in healthy male volunteers. Part A will assess the absorption, metabolism, excretion, and pharmacokinetics of one oral dose of radiolabeled EDG-5506.
- Conditions
- Healthy Volunteer, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases
- Trial name
- NCT05730842
- Testing
- EDG-5506 Tablet, Radiolabeled EDG-5506 Suspension, Radiolabeled EDG-5506 Intravenous
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Edgewise Therapeutics, Inc.
Rheumatoid Arthritis (RA)
A Study of Human Substance Balance and Biotransformation of [14C]SHR0302
The study is being conducted to evaluate the absorption, metabolism and excretion of [14C]SHR0302 in healthy Chinese adult male subjects.
- Trial name
- NCT05047341
- Testing
- SHR0302、[14C]SHR0302
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Glaucoma Open-Angle Primary, Ocular Hypertension
Open-Label Study of Safety of H1337 in Healthy Volunteers
The trial will evaluate the safety of one dose regimen of H-1337 [1% twice daily (b.i.d.)] in both eyes in healthy volunteers.
- Trial name
- NCT06572397
- Testing
- H-1337 1.0%
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- D. Western Therapeutics Institute, Inc.
HIV Infections
A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel
Approximately 112 HIV-negative women, aged 18 to 50, will be enrolled in this multicenter study at four sites. Volunteers will be randomized to dapivirine (TMC120) vaginal gel or matching placebo gel.
- Trial name
- NCT00303576
- Testing
- dapivirine (TMC120) vaginal gel
- Where
- 4 sites in Rwanda, South Africa and 1 more
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
Urinary Calculi, Urinary Stones
Pharmacokinetic and Safety Study of OMS201 in Subjects Undergoing Ureteroscopic Treatment for Removal of Urinary Tract-Located Stones
Evaluate the safety and systemic absorption of OMS201 following exposure during ureteroscopy.
- Conditions
- Urinary Calculi, Urinary Stones, Urinary Tract Stones
- Trial name
- NCT00599664
- Testing
- OMS201, Vehicle
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Omeros Corporation
Psoriasis
Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
The purpose of this study is to evaluate the potential of DFD-06 to suppress the hypothalamic-pituitary-adrenal (HPA) axis when applied twice daily for 15 days.
- Trial name
- NCT03179605
- Testing
- DFD06
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Primus Pharmaceuticals
Peripheral Arterial Disease, Diabetes Mellitus
The Use of HOVR Technology for Assessment of Blood Associated Parameters
Feasibility, usability and safety clinical study that is aimed at testing of the non-invasive VOTIS PedCheck system for measurement of changes in absorption of light in order to derive changes in perfusion and oxygen levels in…
- Trial name
- NCT05921461
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Votis Subdermal Imaging Technologies LTD
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of VX-407 following a single oral dose.
- Trial name
- NCT07868926
- Testing
- 14C-VX-407
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Carcinoma, Renal Cell
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
To study the absorption, distribution, metabolism and excretion of GW786034, and the absorption of a single IV dose of GW786034
- Trial name
- NCT00478725
- Testing
- GW786034, oral, GW786034, IV, GW786034, radiolabeled oral
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Asthma
A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A
GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor that attenuates the production of leukotrienes through the blockage of the first step in the leukotriene pathway, 5-lipoxygenase (5-LO) activation.
- Trial name
- NCT01318980
- Testing
- GSK2190915 100mg milled tablet, [14C] radiolabelled GSK2190915 solution, GSK2190915 100mg milled tablet administered to the proximal small bowel.
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cutaneous T Cell Lymphoma, Mycosis Fungoides
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
Resminostat is a potent, orally available inhibitor of Class I, IIb and IV histone deacetylases (HDACs), including a pronounced activity against HDAC6.
- Conditions
- Cutaneous T Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
- Trial name
- NCT04955340
- Testing
- [14C]-resminostat
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- 4SC AG
Diabetes, Overweight
Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Absorption
Objective - A variety of herbal, over-the-counter preparations of tea leaves are said to reduce the rate of absorption of fat ( allegedly via inhibition of pancreatic lipase) and carbohydrate (via inhibition of carbohydrate…
- Trial name
- NCT00262145
- Testing
- tea extracts
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- NatureGen
Neuroscience
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] AZD2423 in Volunteers
Phase I study to evaluate the excretion of radioactivity, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of [14C]AZD2423 in healthy male volunteers aged 50 to 65 years…
- Trial name
- ADME (NCT01223014)
- Testing
- AZD2423
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca